Carnosine Esters Enzymatic Stability and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for type-2 diabetes are ineffective in the long term and are degraded quickly by carnosinase enzymes, necessitating high doses and lacking in bioavailability and safety.
Innovation Solution
Development of carnosine esters, such as carnosine methyl ester, carnosine ethyl ester, and carnosine iso-propyl ester, which are resistant to enzymatic degradation and have improved bioavailability, allowing for effective regulation of blood glucose levels and treatment of metabolic disorders like type-2 diabetes with minimal toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If carnosine is used as a supplement to scavenge glycation and lipidation end-products, then cellular function is restored in key tissues, but high doses are required due to rapid degradation by carnosinase enzymes
Solution Approach 1:
The patent modifies the chemical structure of carnosine by replacing the terminal amino group with various substituted amino groups ( Formula I), thereby changing the molecular parameters to reduce recognition by carnosinase enzymes while preserving the scavenging activity against glycation and lipidation end-products
Solution Approach 2:
The invention creates composite analogs combining the beta-alanine component with modified amino acid structures that incorporate electron-withdrawing groups, resulting in a hybrid molecule that maintains biological activity while achieving enzymatic stability
2Reliability
If high doses of carnosine are administered to overcome enzymatic degradation, then beneficial effects are achieved, but toxicity increases and bioavailability decreases
Solution Approach 1:
By modifying the amino acid substitution parameters (R1, R2, R3 groups in Formula I), the patent optimizes the balance between therapeutic efficacy and safety, allowing lower doses to achieve the same therapeutic effect with reduced toxicity
Solution Approach 2:
The modified amino acid structures act as intermediaries that resist enzymatic breakdown, serving as a protective mediator that extends the half-life of the active compound in the body, thereby improving bioavailability and reducing required dosage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These esters effectively scavenge reactive species, restore cellular function, and improve insulin secretion and glucose uptake, demonstrating significant clinical benefits in managing type-2 diabetes and related metabolic disorders with improved stability and safety profiles.
Implementation Method 1
carnosine, a naturally occurring physiological dipeptide, is an effective scavenger of glycation and lipidation end-products
Implementation Method 2
there are carnosinase enzymes in both blood and tissues that are able to degrade carnosine
Data Source
AI summary
The invention provides a compound of Formula (I) or a tautomer, isomer, prodrug, metal complex, or pharmaceutically acceptable salt thereof for use in the treatment of a metabolic disorder, wherein R1 is: a straight or branched C1-C20 alkoxy, preferably C1-C10 alkoxy group, optionally containing one or more rings, and/or optionally containing one or more double bonds; an alkoxycarbonyloxyalkoxy group bearing a straight, branched or cyclic alkyl; an aryloxy group; or an arylalkoxy group; R2 and R3 which can be the same or different, are: hydrogen; a straight or branched C1-C20 alkylcarbonyl or cyclic C3-C7 alkylcarbonyl group optionally containing one or more double bonds; an arylcarbonyl or arylalkylcarbonyl group; a straight or branched C1-C10 alkoxycarbonyl or cyclic C3-C7 alkoxycarbonyl group optionally containing one or more double bonds; an arylalkoxy carbonyl group; an amino group; a hydroxy group; or a group of general Formula (II) wherein Y is nitrogen, oxygen or sulfur and A is hydrogen or an amino group.